Prevalence of and Factors Associated With Extraintestinal Manifestations and Their Remission in Inflammatory Bowel Disease: The EXTRA-Intestinal Manifestation Prospective Study From the Groupe d'Etude Thérapeutique des Affections Inflammatoires du Tube Digestif

Author:

Guillo Lucas1,Savoye Guillaume2,Amiot Aurélien3,Gilletta Cyrielle4,Nachury Maria5,Dib Nina6,Bourreille Arnaud7,Roblin Xavier8,Caillo Ludovic9,Allez Matthieu10,Picon Laurence11,Hébuterne Xavier12,Seksik Philippe13,Chupin Antoine14,Buisson Anthony15,Brixi Hédia16,Altwegg Romain17,Simon Marion18,Amil Morgane19,Laharie David20,Bouguen Guillaume21,Serrero Mélanie1,Elgharabawy Yasmine22,Peyrin-Biroulet Laurent23,

Affiliation:

1. Department of Gastroenterology, University Hospital of Marseille Nord, University of Aix-Marseille, Marseille, France;

2. Department of Gastroenterology, Rouen University Hospital, Rouen, France;

3. Department of Gastroenterology, Groupe Hospitalier Henri Mondor-Albert Chennevier, APHP, EC2M3-EA7375, University of Paris Est Créteil, Créteil, France;

4. Department of Gastroenterology, Toulouse University Hospital, Toulouse, France;

5. Université de Lille, Inserm, CHU Lille, U1286–INFINITE–Institute for Translational Research in Inflammation, Lille, France;

6. Hepato-Gastroenterology Department, Angers University Hospital, Angers, France, HIFIH Laboratory, UPRES 3859, SFR 4208, Angers University, Angers, France;

7. Department of Gastroenterology, Institut des Maladies de l'Appareil Digestif (IMAD), CIC Inserm 1413, Nantes University Hospital, Nantes, France;

8. Department of Gastroenterology, Saint-Etienne University Hospital, Saint-Etienne, France;

9. Department of Gastroenterology, University Hospital of Nimes, Nimes, France;

10. Department of Gastroenterology, Hôpital Saint Louis, Assistance Publique–Hôpitaux de Paris, INSERM U1160, Université Paris Cité, Paris, France;

11. Department of Gastroenterology, Tours University Hospital, Tours, France;

12. Gastroenterology and Clinical Nutrition, CHU of Nice, University Côte d'Azur, Nice, France;

13. Department of Gastroenterology, Centre de Recherche Saint-Antoine, Sorbonne Université, INSERM, APHP, Hôpital Saint-Antoine, Paris, France;

14. Department of Gastroenterology, Georges-Pompidou European Hospital, Paris, France;

15. Université Clermont Auvergne, 3iHP, CHU Clermont-Ferrand, Service d'Hépato-Gastroentérologie, Inserm U1071, M2iSH, USC-INRA 2018, Clermont-Ferrand, France;

16. Department of Gastroenterology, Reims University Hospital, Reims, France;

17. Department of Gastroenterology, Saint-Eloi Hospital, University Hospital of Montpellier, Montpellier, France;

18. Department of Gastroenterology, Institut Mutualiste Montsouris, Paris, France;

19. Departement of Gastroenterology, Les Oudairies Hospital, La Roche-sur-Yon, France;

20. CHU de Bordeaux, Hôpital Haut-Lévêque, Service d'Hépato-Gastroentérologie et Oncologie Digestive, Université de Bordeaux, Bordeaux, France;

21. Department of Gastroenterology, Centre Hospitalier Universitaire Pontchaillou, Rennes, France;

22. Groupe d'étude Thérapeutique des Affections Inflammatoire du Tube digestive (GETAID), Paris, France;

23. Department of Gastroenterology and Inserm NGERE U1256, University Hospital of Nancy, University of Lorraine, Vandoeuvre-lès-Nancy, France.

Abstract

INTRODUCTION: Extraintestinal manifestations (EIMs) of inflammatory bowel disease (IBD) are challenging clinical situation. No prospective study assessed remission risk factors of EIMs. The aim of this study was to prospectively investigate the epidemiology, risk factors of EIM occurrence, and EIM remission in a large IBD cohort. METHODS: We conducted a cross-sectional study in 30 French referral centers. Between May 2021 and June 2021, all consecutive patients attending to hospital appointment were systematically invited to fill out a questionnaire. RESULTS: A total of 1,971 consecutive patients with IBD were analyzed. There were 1,056 women (53.8%), and the median age of patients was 41 years (31–54). The median disease duration was 11 years (1–18). Overall, 544 (27.6%) had at least 1 EIM. In 20.2% of cases, patients had multiple EIMs. The most frequent EIMs were rheumatological (19%) and dermatological (10%) manifestations. Immunosuppressant treatment (odds ratio [OR] = 2.56; P < 0.001) was a risk factor of EIM, while the Montreal A3 classification (OR = 0.61, P = 0.023) and male gender (OR = 0.61, P < 0.001) were associated with a lower risk of EIM occurrence. IBD current clinical remission (OR = 2.42; P < 0.001) and smoking cessation (OR = 2.98; P < 0.001) were associated factors of EIM remission. Conversely, age at IBD diagnosis (OR = 0.98; P < 0.018) was associated with a lower risk of EIM remission. DISCUSSION: One quarter of patients had at least 1 EIM. Beyond factors associated with the presence of EIMs, patients with IBD current clinical remission and smoking cessation are more likely to achieve EIM remission, while increasing age at IBD diagnosis is associated with decreased chance of remission.

Funder

Pfizer

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Gastroenterology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3